The European Medicines Agency has accelerated the approval process for a Covid-19 vaccine developed by Germany’s BioNTech and US pharma group Pfizer, to allow for the rapid authorisation of the shot as soon as safety data from its trial allows.
欧洲药品管理局(EMA)已加快对德国BioNTech和美国制药集团辉瑞(Pfizer)开发的一款新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗的批准程序，以便在试验安全性数据允许的情况下迅速批准该疫苗。
您已阅读9%（353字），剩余91%（3718字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。